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962Objectives: Ventricular remodeling after myocardial infarction begins with massive extracellular matrix depo-
sition and resultant fibrosis. This loss of functional tissue and stiffening of myocardial elastic and contractile
elements starts the vicious cycle of mechanical inefficiency, adverse remodeling, and eventual heart failure.
We hypothesized that stromal cell–derived factor 1a (SDF-1a) therapy to microrevascularize ischemic myocar-
dium would rescue salvageable peri-infarct tissue and subsequently improve myocardial elasticity.
Methods: Immediately after left anterior descending coronary artery ligation, micewere randomly assigned to re-
ceive peri-infarct injection of either saline solutionor SDF-1a. After 6weeks, animalswere killed and sampleswere
taken from the peri-infarct border zone and the infarct scar, as well as from the left ventricle of noninfarcted control
mice.Determination of tissues’ elasticmoduliwas carried out bymechanical testing in an atomic forcemicroscope.
Results: SDF-1a–treated peri-infarct tissue most closely approximated the elasticity of normal ventricle and
was significantly more elastic than saline-treated peri-infarct myocardium (109  22.9 kPa vs 295  42.3
kPa; P<.0001). Myocardial scar, the strength of which depends on matrix deposition from vasculature at the
peri-infarct edge, was stiffer in SDF-1a–treated animals than in controls (804  102.2 kPa vs 144  27.5
kPa; P<.0001).
Conclusions: Direct quantification of myocardial elastic properties demonstrates the ability of SDF-1a to re-
engineer evolving myocardial infarct and peri-infarct tissues. By increasing elasticity of the ischemic and
dysfunctional peri-infarct border zone and bolstering the weak, aneurysm-prone scar, SDF-1a therapy may
confer a mechanical advantage to resist adverse remodeling after infarction. (J Thorac Cardiovasc Surg
2012;143:962-6)Current therapies for ischemic heart disease consist of phar-
macologic optimization and limited revascularization, re-
constructive, or replacement options. These modalities,
however, are effective for only a fraction of patients.
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The Journal of Thoracic and Cardiovascular Surgdeficiencies that persist even when an occluded artery is
stented or bypassed nor the abnormal mechanical stress
and loading of the infarct and perfused viable border zone
region adjacent to the infarct.
It has been shown that immediately after the onset of is-
chemia, abnormal ventricular loading results in thinning
and stretching of the infarct, as well as increased mechani-
cal stress in the peri-infarct border zone. In addition, it has
been demonstrated experimentally that infarct expansion is
associated with progressive loss of contractile function in
the perfused border zone adjacent to the infarct and that
this dysfunctional region becomes more hypocontractile
and begins to involve additional perfused myocardium as
remodeling continues and heart failure progresses.1,2
Also, after an infarction, the extent of microvascular
obstruction increases greatly during the first 48 hours, and
there is significant progressive microvascular and
myocardial injury well beyond the infarct zone, even with
reperfusion.3,4 This is important because an increase in
the number of capillaries has been correlated with
increases in both contractility and function under stress
conditions.5 Endogenous repair machinery is inadequate
to correct this deficiency, and tremendous resources haveery c April 2012
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hance both the microvascular perfusion and the function
of ischemic or infarcted myocardium.
Stromal cell–derived factor 1a (SDF-1a) is a key regula-
tor of physiologic cell motility during both embryogenesis
and after birth and is constitutively expressed in a wide va-
riety of cells, including endothelial cells, dendritic cells,
and stromal cells.6 This powerful chemoattractant is signif-
icantly upregulated in response to both myocardial ische-
mia and infarction and has been shown to effect
endothelial progenitor cell proliferation and mobilization
to induce vasculogenesis.7,8 Experimentally, in both
mouse and rat models, peri-infarct myocardial injection of
SDF-1a has been shown to significantly enhance myocar-
dial endothelial progenitor cell density, to increase vasculo-
genesis and capillary density, and to augment myocardial
function by enhancing perfusion, reversing cellular ische-
mia, increasing cardiomyocyte viability, and ultimately pre-
serving ventricular geometry.8-16
An ideal therapy to stem the tide of infarct expansion
would be one that could both stiffen and reinforce the fi-
brotic myocardial scar to reduce the cardiac wall stress in
an injured ventricle while simultaneously rescuing the
dysfunctional peri-infarct border zone by addressing themi-
crovascular deficit and normalizing the elasticity of the vi-
able myocardium. In this study, it was our hypothesis that
angiogenic border zone SDF-1a therapy would yield
a less stiff, more elastic, more mechanically efficient
myocardium.
MATERIALS AND METHODS
Animal Care and Biosafety
Male CD-1 mice (n ¼ 18) weighing 25 to 30 g were obtained from
Charles River (Charles River Laboratories International, Inc, Wilmington,
Mass) and randomly assigned in equal groups to receive direct intramyo-
cardial injection of either saline solution (30 mL) or SDF-1a (6 mg/kg in
30 mL) after infarction or to undergo no infarction. Food and water were
provided ad libitum. This investigation was performed in accordance
with the Guide for the Care and Use of Laboratory Animals published
by the US National Institutes of Health (NIH Publication No. 85-23, re-
vised 1996; www.nap.edu/catalog/5140.html) and was approved by the in-
stitutional animal use and care committee of the University of Pennsylvania
(protocol No. 709026).
Ischemic Cardiomyopathy Model
Micewere anesthetized with ketamine hydrochloride [INN ketamine] at
100 mg/kg and xylazine at 10 mg/kg, intubated with a 22-gauge catheter,
and mechanically ventilated (Hallowell EMC, Pittsfield, Mass). With the
animal supine, an anterior thoracotomy was performed in the left fourth in-
tercostal space, and an 8-0 polypropylene suture was placed around the left
anterior descending coronary artery midway between the left atrialThe Journal of Thoracic and Caappendage and left ventricular apex and ligated to produce a large antero-
lateral myocardial infarction of approximately 30% of the left ventricle.
The extent of infarction has been highly reproducible in our hands, and pro-
gression to cardiomyopathy has been well documented.14 After ligation,
animals were randomly assigned to receive direct intramyocardial injection
into the peri-infarct border zone of either saline solution (30 mL, n ¼ 6) or
SDF-1a (6 mg/kg in 30 mL, n¼ 6). Injections were given in 3 divided doses
of 10 mL to 3 predetermined locations, which consisted of the peri-infarct
myocardium to the right and left of the ligating suture and the left ventric-
ular apex. The thoracotomy was then closed, and the animals were extu-
bated and allowed to recover. Buprenorphine hydrochloride [INN
buprenorphine] was administered at 0.5 mg/kg for postoperative analgesia.
The SDF-1a treatment group received subcutaneous injections of 40 mg/kg
liquid sargramostim (granulocyte macrophage colony-stimulating factor),
diluted in saline solution for a total volume of 100 mL immediately postop-
eratively and on postoperative day 1.We did not include a control group that
received subcutaneous injections of granulocyte macrophage colony-
stimulating factor because the preponderance of literature has demonstrated
no difference between control groups receiving intramyocardial saline so-
lution injection only and groups receiving saline solution injection plus sub-
cutaneous granulocyte macrophage colony-stimulating factor.9,10,12,13
Determination of Myocardial Elastic Modulus
Six weeks after surgery, the animals were killed, and multiple myocar-
dial samples were taken from the peri-infarct border zone and the infarct
scar of each animal. Samples were also taken from the left ventricle of non-
infarcted control mice (n ¼ 6). Tissue specimens were cut into small, thin
pieces (33 33 1 mm), fixed to glass microscope slides, and stored in Dul-
becco’s modified Eagle medium buffer solution (Gibco; Life Technologies
Corporation, Grand Island, NY; Figure 1). Determination of the tissues’
elastic moduli was carried out by mechanical testing in an atomic force mi-
croscope (Asylum MFP-3D; Asylum Research, Santa Barbara, Calif).
Force–distance measurements were performed 20 to 30 times at 1 or
more locations on each specimen at the rate of 1 Hz. Each tissue sample
was probed an average of 25 times (range, 14–41 times), for a total of
1966 data points. The measurements for each separate group were then ag-
gregated and compared. The atomic force microscope probes’ optical sen-
sitivities were determined first on dry glass slides to determine their spring
constant and again on glass within the buffer solution to account for absorp-
tion of the light by the buffer. Stiffness measurements were then carried out
within the buffer. The elastic modulus was determined by analyzing the
force curves generated by pressing the probe into the tissue and recording
the cantilever deflection. The Herzian-Sneddon model of a cone indenting
an elastic half-space has previously been used in similar measure-
ments.17,18 In this analysis, the Young modulus of a material (E) is given
by the following equation:
E ¼ d$k$pð1v
2Þ
2d2tanðaÞ
where d is the cantilever deflection, k is its bending spring constant, n is the
material Poisson ratio (assumed to be 0.5), d is the indentation distance, and
a is the half-angle of the cone. MATLAB (The MathWorks, Inc, Natick,
Mass) scripts were written to batch process the force curves and find the
slope of d versus d2 lines, which yielded the elastic modulus E (Figure 2).
Statistical Analysis
The unpaired Student t test was used to compare groups. Values are ex-
pressed as mean  SEM.RESULTS
Force–distance measurements were performed 20 to 30
times at 1 or more locations on each specimen at the raterdiovascular Surgery c Volume 143, Number 4 963
FIGURE 3. By increasing the elasticity of the dysfunctional peri-infarct
border zone and stiffening the infarct scar, stromal cell–derived factor 1a
(SDF) therapymay confer a mechanical advantage in resisting adverse ven-
tricular remodeling after infarction.
FIGURE 1. Immediately after left anterior descending coronary artery
ligation (asterisk indicates exact point of suture ligation), animals were ran-
domly assigned to receive intramyocardial injection of either stromal cell–
derived factor 1a or saline solution into the peri-infarct border zone
(shaded in blue). Dashed circles (black for border zone; white for scar) in-
dicate tissue removed and mounted for atomic force microscopy 6 weeks
after surgery. LV, Left ventricular.
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times (range, 14–41 times), for a total of 1966 data points.
Ventricular tissue from noninfarcted mice was significantly
more elastic (60.4 2.6 kPa; P<.02) than any of the tissue
regions measured from mice that had undergone left ante-
rior descending coronary artery ligation, regardless of
whether they had received SDF-1a; however, SDF-1a–
treated peri-infarct border zone most closely approximated
the elasticity of normal left ventricle and was significantly
more elastic than peri-infarct myocardium treated with sa-
line solution (109  22.9 kPa vs 295  42.3 kPa;
P<.0001). Consistent with the presumed angiogenic mech-
anism of action of SDF-1a, the myocardial scar proper, theFIGURE 2. In this analysis, the Young modulus of a material is E, where
d is the cantilever deflection, k is its bending spring constant, n is the ma-
terial Poisson ratio (assumed to be 0.5), d is the indentation distance, and
a is the half-angle of the cone. MATLAB (The MathWorks, Inc, Natick,
Mass) scripts were written to batch process the force curves and find the
slope of d (blue) versus d2 (red) lines, which yielded E.
964 The Journal of Thoracic and Cardiovascular Surgstrength of which is dependent of on fibroblast and collagen
deposition from vasculature at the peri-infarct edge, was
stiffer in SDF-1a–treated animals than in control animals
(804  102.2 kPa vs 144 þ 27.5 kPa, P < .0001;
Figure 3). Indentation depth was less than 1 mm for nearly
all measurements, meaning the base of the cantilever ad-
vanced 1 mm or less between making contact with the tissue
and turning back around. This should not be confused with
cantilever deflection or actual penetration into the tissue.
All of the measurements were performed at 1 Hz, but the ac-
tual velocity depended also on the amount of retraction
needed to ensure complete separation of the probe tip
from the myocardial tissue sample.DISCUSSION
Currently, many groups are exploring the use of inject-
able or implantable materials to limit infarct expansion
and to return the postinfarct myocardial stress distribution
to normal.19-25 A wide range of cell and material types
with varying properties have been tested, mostly as
a bolster to the infarct scar proper, with the ultimate goal
being to reduce strain on the peri-infarct border zone and
prevent infarct expansion. In this experiment, we ap-
proached this problem from a novel direction. We know
that patients with robust angiographic collateralization after
an infarct manifest improved regional ventricular function
and that SDF-1a has repeatedly been shown to play a critical
role in the rescue of myocardial function, stem cell recruit-
ment to the heart after myocardial infarction, and improved
microrevascularization.8-11,14-16,26-30 In light of this
information, we hypothesized that angiogenic peri-infarct
SDF-1a therapy would yield a less stiff, more elastic,
more mechanically efficient myocardium. Because of the
preponderance of historical data, we have speculated thatery c April 2012
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mented peri-infarct microvascular bed, will provide an in-
crease in dynamic flow reserve to these areas of maximal
mechanical stress. We believe that the enhanced capillarity
in the peri-infarct border zone will help to alleviate biome-
chanical stress, prevent ultrastructural alterations, and im-
prove cardiomyocyte viability, yielding a less stiff, more
elastic, more mechanically efficient myocardium, which
could ultimately prevent remodeling and improve ventricu-
lar performance. In addition, increased vasculature at the
peri-infarct edge may intensify myofibroblast accumulation
in the infarct scar proper, producing large amounts of extra-
cellular matrix proteins, which will ultimately stiffen and
provide mechanical support to the ventricle.31
This experiment has demonstrated that SDF-1a treat-
ment to the peri-infarct border zone at the time of myocar-
dial infarction does in fact re-engineer the evolving
myocardial infarct and peri-infarct tissue. Determination
of the myocardial elastic moduli was carried out by direct
mechanical testing in an atomic force microscope incorpo-
rating nearly 2000 data points, and this revealed that
peri-infarct border zone tissue treated with SDF-1awas sig-
nificantly more elastic than peri-infarct border zone tissue
treated with saline solution and more closely approximated
normal, noninfarcted ventricle. Additionally, it was found
that the infarct scar in SDF-1a–treated animals was much
stiffer than the infarct scar in control animals. This is impor-
tant, because it has been shown that stiffer infarcts are asso-
ciated with improved ventricular function and less
progression toward heart failure.32,33 It is wholly possible
that the changes seen in SDF-1a–treated border zone
actually follow from changes to the scar itself. This would
still be consistent with the presumed angiogenic
mechanism of action of SDF-1a, because the strength of
the myocardial scar is dependent on fibroblast and
collagen deposition from vasculature at the peri-infarct
edge.
The application of atomic force microscopy to determine
the myocardial elastic modulus directly was both a great
strength of the study and a potential source of error.
When using the atomic force microscope, there are 4 major
areas for possible error: indentation velocity, indentation
distance, contact point assignment, and data sampling
rate. To combat these potential pitfalls, we limited indenta-
tion rates to less than 2 mm/s, which appropriately explored
the elastic rather than the viscoelastic properties of cells and
extracellular matrix.34 Indentation depth was in fact less
than 1 mm for most measurements and was performed at
a rate of 1 Hz.35,36 Contact points assigned through the
Domke-Radmacher formula (which allows for the determi-
nation of the contact point when the atomic force micro-
scope tip first makes contact with a soft material) rely on
accurate selection of the appropriate analysis range37 and
require the data sampling rate to be slowed appropriatelyThe Journal of Thoracic and Cato accommodate indentation rates, repeated measurements
at each site, and spatial movement to the next site of mea-
surement. Also, tensile strength is a uniaxial measurement
that varies with tissue strip orientation, because normal
myocardium and healing infarcts are anisotropic tissues.
To minimize anisotropic differences in tensile strength,
we very carefully tried to dissect the tissues reproducibly
and to measure the tissue strips in a uniform direction.38
In conclusion, SDF-1a therapy may confer a mechanical
advantage in resisting adverse ventricular remodeling and
infarct expansion by increasing the elasticity of the dys-
functional peri-infarct border zone and bolstering the
weak, aneurysm-prone scar. Treatment with SDF-1a also
offers a clinically translatable, potentially noninvasive or
catheter-based therapy that could be deployed at any point
in the time course of ischemic heart disease and can address
critical deficits in microvascular perfusion as well as alter
myocardial biomechanical material properties.
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